Genetic testing is increasingly used as a means to guide treatment across several cancer types, and particularly ovarian cancer, where inherited mutation in the BRCA1 or BRCA2 genes is an established risk factor. We begin this next session on gynecologic cancers with Dr Sarah Paraghamian from Tufts Medicine, who will discuss the use of genetic testing in ovarian cancer patients with early and recurrent disease.

To obtain credit for this CME activity you must watch the full 2022 Evolution Conference Playlist. Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.

свернуть